OmniChart

LEK Juliette 08 Sep 2015

Highlander & DelBoy Trading: thankfully i don't think anyone listens to Highlander.

MSMN hobione 08 Sep 2015

RNS Wow the presentation points to 8000 bopd production for the new field!!!! That is some target. At this market cap even if they get to half of that target it'll 5 bag. IMHO DYOR

FKL corriedog 08 Sep 2015

Trading statement Not good not bad but ok. Still generating cash with £9.5m in the bank. With a market cap of £28m the three trading businesses are only valued at £18.5m or about 3.5 times EBITDA..

LEK hobione 08 Sep 2015

Producing oil company Oil flowing cash will flow too and plenty of cheap assets to be snapped up in Africa too. Watch this company expand and become a big player. You heard it here first.

AUE laurence 08 Sep 2015

it is all on lease

RXP CuttySarkRIP 08 Sep 2015

Re: RNS OPS UPDATE - muddy fluid When is fluid not fluid? When it's muddy drilling fluid?[link]

PCI spike68 08 Sep 2015

Someone not happy [link]

FOGL harpmandoodle 08 Sep 2015

Well if they can't finish this one, what's the point of going back to Isobell?

ACP mog 08 Sep 2015

Ask yourselves this, why hasnt there been a single posting on acp since the end of June on interactive investors, Maybe cause all the rampers are on here.Dont you find that strange. Because I certainly do. Why only on here?

LOGP forwardloop 07 Sep 2015

Lansdowne Oil & Gas still has substantial asset [link] is useless to pretend that the plugging and abandoning some weeks back of the 49/11-3 well on the Midleton field in the Celtic Sea is anything but a great disappointment for Dublin-headquartered Lansdowne Oil & Gas.(LON:LOGP).The well is close to Kinsale Head, which is Ireland’s only producing gas field.The oil explorer has a 20% stake in the Midleton concession but once owned 100%. It is some consolation that the operator Kinsale Energy, which farmed-in for 80% of Midleton, fully carried Lansdowne’s share of the drilling costs of 49/11-3.It is, nevertheless, a blow to Lansdowne at a time when it hoped that a new discovery would re-ignite the company’s share price, which had been becalmed for some time because of a perceived lack of activity.This operation is very much in line with Lansdowne’s core business model, which is to acquire licences that usually have proven reserves not yet exploited.It then gets a major company to farm in, because it has the financial muscle and technical wherewithal to develop potentially high impact fields which could then become company-making for a minority shareholder like Lansdowne.Lansdowne has interests in six other licences in the Celtic Sea, including Helvick where there is a 10% interest, Amerigen with a 100% stake and Barryroe where there is a 20% involvementMidleton has been estimated to contain 268bn cubic feet of recoverable gas resources, so it seemed like a major prize to go for. The company’s own literature said that a success at Midleton could be worth a multiple of its current market capitalisation which is £4.65mln.But the fact that the well found non-commercial amounts of gas meant the share price, which had almost doubled to 7.7pence on expectations of good news fell back to 3.13p when the not-so-good- news broke, and today is at a 52 week low of 2.37p.Speaking to Proactive Investors, Lansdowne chief executive Steve Boldy said at the time: “Yes, the Midleton well result is very disappointing because a successful well could have added a lot of value for shareholders, but we still have substantial resources in the Celtic Sea via our 20% interest in Barryroe”.A discovery was originally made on Barryroe back in 1973 by Marathon, but nothing was done about it. Providence Resources (LONVR), another Dublin–based group that became the operator with an 80% stake in Barryroe, acquired a 3D seismic survey over the field in 2011 before drilling the 48/24 - 10z well, which tested 4,000 barrels of oil equivalent (boepd) in 2012.Independent reservoir engineers Netherland, Sewell & Associates Inc. (NSAI) has estimated the Basal Wealden zone contains contingent resources of 290mln barrels of oil equivalent (mmboe) while RPS Energy, another independent assessor, put the figure for the Middle Wealden at 49 mmboe, thus establishing a potentially very substantial resource.Hats were thrown in the air in delight in Dublin. Providence announced the flow rate because it seemed the venture (JV) partners had made a world class discovery, which would not only reward the companies greatly but also benefit Ireland’s economy. Barryroe is so far Ireland’s only known potentially commercial oil field.Unfortunately, the excitement surrounding the prospect has faded because Providence has found it difficult to find a farminee to develop the project.After more than a year of casting around for a farm-in partner Providence confirmed in February that it had, at last, reached agreement on commercial terms with a proposed farminee, but that the closing of the deal was conditional on the would-be partner raising funds.The Dublin-based company reminded shareholders that there is no certainty that the farm-in will be concluded with the proposed

OXP pharmaspecialist 07 Sep 2015

Unimpressed I am amazed at the lack of information about the company's formulation technology on the web site as this is critical to the company's success. Unless I have missed something, there does not seem to be much scientic validation of this technology either, where did it originate? Even the 2014 annual report is a bit sketchy about the technology. Biotech companies normally like to publicise their technologies and if they are any good, they would normally be patented so no risk from competitors. If I were an investor I would also be concerned about the July 31 press release saying that the pilot clinical study of OXPzero™ Naproxen produced "encouraging results". The results were not encouraging because there was no evidence that the OXPzero drug reduced gastrointestinal irritation and the reduction in the number of erosions was not statistically significant, in fact I would say that this study raises questions over whether the company's formulation technology (whatever it is) works. I hope Mr. Woodford got a biotech specialist to do due diligence on this company before he invested!

SAR Elena Saratov 07 Sep 2015

Re: low Very much a share for the braver investor.Good time to buy here.Moving up from the low.This share moves very quickly when it moves so make sure you get in beforehand.If you need safety then buy something else.

POS II Editor 07 Sep 2015

NEW ARTICLE: Trends and Targets for 8/09/2015 " PLEXUS PLC (LSEOS) continues our Oil Equipment, Services & Distribution Sector week. There's quite a lot not to like due to recent price movements but we've a vague hope some sort of near term bounce can be hoped from the Red Dash line as ..."[link]

SER Forest73 07 Sep 2015

Re: Lights back on ! lights on staff to check now. At these levels a small nothing to lose.

MTPH pharmaspecialist 07 Sep 2015

Midatech equity cheaper in US If you are looking to buy Midatech for the long term you might like to consider buying a stake via its takeover target, Dara Biosciences in the US. As the press release states "The exchange ratio is subject to an implied acquisition price range of $1.08 to $1.32 per DARA share". At current prices the implied Dara price is nearer $1.08 than $1.32 but Dara is actually trading at $0.84 on NASDAQ so you effectively get a 20%+ discount on Midatech equity, assuming the deal goes through. You will end up with Midatech ADRs quoted on NASDAQ which may be less liquid that UK quoted Midatech shares, but I am sure there will be more US acquisitions to be merged with Dara so this should not be a long term problem. You even get an extra sweetener with Dara shares as there is a potential cash payment to ADR holders if sales of Dara's drugs are better than expected after the Midatech takeover. One thing I would say is don't rely on Mr. Woodford's judgement when investing in biotech. I'm sure he is a brilliant equity income investor but I find it bizarre that he is now investing in biotech - it's a bit like Anthony Bolton investing in China, only worse.